Souvik Banerjee | Research & Reviews | University of Te

Souvik Banerjee

Souvik Banerjee

Souvik Banerjee
Research Associate
Department of Pharmaceutical Sciences
University of Tennessee Health Science Center (UTHSC)
USA

 
 

Biography

Souvik Banerjee is a Research Associate in the department of Pharmaceutical Sciences at the University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA. He is a member of American Chemical Society, division of Organic Chemistry. Additionally, he is the Secretary and News Letter Editor of Memphis Local Section of the American Chemical Society. Dr. Banerjee earned his Ph.D. in Organic Chemistry from the University of Southern Mississippi in 2013. Prior to joining Ph.D., Dr. Banerjee worked as a Scientist in the Biocon Biopharmaceuticals, a leading biotechnology company in India from 2005-2008. Following his Ph.D., He has undergone three years of post-doctoral training in Medicinal Chemistry at the UTHSC under the mentorship of Professors. Duane D. Miller and Gabor J. Tigyi. Upon completion of his postdoctoral training, he joined the College of Pharmacy at the UTHSC as a Research Associate in Medicinal Chemistry since February, 2017. His research in Organic as well as in Medicinal Chemistry has resulted in a number of internationally peer reviewed journals and a pending U.S. patent. His research is mainly focused on anticancer drug discovery that includes Autotaxin Inhibitors, Tubulin Polymerization Inhibitors, Lysophosphatidic Acid Receptors (LPARs) antagonists, Estrogen Receptor Beta Agonists, and Somatostatin Peptide analogues consisting of unnatural amino acids.

 

Research Interest

Discovery of new potent small molecule Auotaxin Inhibitors and dual Inhibitors of Autotaxin and Lysophosphatidic Acid Receptor 1 (LPA1) targeting cancer invasion and metastasis, discovery of highly potent small molecule Tubulin Polymerization Inhibitors and Nanoparticle Drug Delivery targeting Vascular Disruption, discovery of small molecule Estrogen Receptor Beta Agonists as anticancer as well as anti-obesity drugs.